ProCE Banner Activity

MATTERHORN: Interim Results From a Phase III Trial of Durvalumab + FLOT in Resectable Gastric and Gastroesophageal Junction Cancer

Conference Coverage

In the phase III MATTERHORN trial, the addition of durvalumab to perioperative FLOT in patients with gastric and gastroesophageal junction cancer was associated with a significant improvement in pCR rate.

Released: October 25, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc